公开(公告)号：EP4355372A1

公开(公告)日：2024-04-24

申请号：EP22823978.6

申请日：2022-05-13

申请人： Suzhou Fuse Biosciences Limited

发明人： LI, Qufei ,  BAILEY, Lucas

IPC分类号： A61K47/68 ,  C07K19/00 ,  C07K14/52

CPC分类号： A61P35/00 ,  C07K2317/3120130101 ,  C07K14/55 ,  C07K2319/3320130101 ,  C07K2319/3520130101 ,  C07K16/40 ,  C07K19/00 ,  C07K2317/7120130101 ,  C07K2317/56520130101 ,  C07K2317/3420130101 ,  C07K16/244 ,  C07K2317/9220130101 ,  C07K2317/9420130101 ,  A61K2039/50520130101 ,  C07K16/30 ,  A61K47/6813 ,  A61K47/6879 ,  A61K47/6851

公开(公告)号：EP3371223A1

公开(公告)日：2018-09-12

申请号：EP16810243.2

申请日：2016-10-27

申请人： Merck Patent GmbH

发明人： DOERNER, Achim ,  TOLEIKIS, Lars ,  SOOD, Vanita, D. ,  SELLMANN, Carolin ,  KNUEHL, Christine

IPC分类号： C07K16/28

CPC分类号： A61K47/6803 ,  A61K47/68 ,  A61K47/6849 ,  A61K47/6879 ,  A61P35/00 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

摘要： A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.

公开(公告)号：EP3223848A4

公开(公告)日：2018-07-18

申请号：EP15862509

申请日：2015-11-26

申请人： ZYMEWORKS INC

发明人： WICKMAN GRANT RAYMOND ,  NG GORDON YIU KON ,  WEISSER NINA E

IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC分类号： C07K16/32 ,  A61K39/395 ,  A61K47/6803 ,  A61K47/6855 ,  A61K47/6869 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

摘要： Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

公开(公告)号：EP3253414A1

公开(公告)日：2017-12-13

申请号：EP16746010.4

申请日：2016-02-05

申请人： The University Of Queensland

发明人： THURECHT, Kristofer ,  HOWARD, Christopher ,  MAHLER, Stephen

IPC分类号： A61K39/44 ,  A61K39/00 ,  A61K47/30 ,  A61K47/00 ,  C12N11/00 ,  C12N11/08

CPC分类号： C07K16/44 ,  A61K9/5146 ,  A61K47/60 ,  A61K47/6835 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6879 ,  A61K49/0054 ,  A61K49/0058 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/3092 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/92 ,  G01N33/545

摘要： Disclosed are targeting constructs for targeting a target site, including a molecule or complex of interest. The targeting constructs comprise a polymer chain and a plurality of multi-specific molecules each of which includes an affinity moiety for binding with the polymer chain and a targeting ligand for binding with the target site. The polymer chain may be associated with a therapeutic or diagnostic agent and generally comprises a plurality of sites, wherein individual sites bind with a multi-specific molecule of the target construct. The present disclosure also relates to methods of preparing the targeting construct and to its use in therapeutic and diagnostic applications.

公开(公告)号：EP3200823A2

公开(公告)日：2017-08-09

申请号：EP15845573.3

申请日：2015-10-02

申请人： City of Hope

发明人： WILLIAMS, John, C.

IPC分类号： A61K39/395 ,  C07K4/00 ,  C07K16/00

CPC分类号： C07K16/32 ,  A61K47/60 ,  A61K47/6801 ,  A61K47/6879 ,  A61K47/6889 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/00 ,  C07K16/2803 ,  C07K16/2863 ,  C07K2317/35 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/77 ,  C07K2317/92

摘要： Provided are methods for altering the distribution of a cell surface antigen. Also provided are compositions for use in the methods, including multivalent meditopes, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.

摘要翻译： 提供了改变细胞表面抗原分布的方法。 还提供了用于所述方法的组合物，包括多价中间位，以及生产，使用，测试和筛选所述组合物的方法，包括治疗和诊断方法和用途。

公开(公告)号：EP3164419A1

公开(公告)日：2017-05-10

申请号：EP15732216.5

申请日：2015-06-25

申请人： F. Hoffmann-La Roche AG

发明人： BRINKMANN, Ulrich ,  GEORGES, Guy ,  AUER, Johannes ,  LAU, Wilma

IPC分类号： C07K16/44

CPC分类号： C07K16/44 ,  A61K47/549 ,  A61K47/62 ,  A61K47/6803 ,  A61K47/6879 ,  C07K16/2881 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/624

摘要： The invention provides anti-BRDU antibodies and methods of using the same.

摘要翻译： 本发明提供了抗BrdU抗体和使用它们的方法。

公开(公告)号：EP3089759A1

公开(公告)日：2016-11-09

申请号：EP14825155.6

申请日：2014-12-29

申请人： F. Hoffmann-La Roche AG

发明人： BRINKMANN, Ulrich ,  HOFFMANN, Eike ,  DENGL, Stefan ,  MAYER, Klaus

IPC分类号： A61K47/48 ,  A61P35/00 ,  C07K16/44

CPC分类号： C07K16/44 ,  A61K38/45 ,  A61K47/557 ,  A61K47/6817 ,  A61K47/6829 ,  A61K47/6835 ,  A61K47/6879 ,  A61K47/6893 ,  C07K16/00 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/94 ,  C12Y204/02036

摘要： Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.

摘要翻译： 本文报道了半抗原多肽毒素和抗半抗原抗体的缀合物，其中在用于半抗原缀合的赖氨酸残基之前或之后的半胱氨酸残基之间形成二硫键，并且其中CDR2中的半胱氨酸残基 抗体，由此根据Kabat测定CDR2。

公开(公告)号：EP3089758A1

公开(公告)日：2016-11-09

申请号：EP14821205.3

申请日：2014-12-29

申请人： F.Hoffmann-La Roche AG

发明人： BRINKMANN, Ulrich ,  GEORGES, Guy ,  HOFFMANN, Eike ,  TIEFENTHALER, Georg ,  MOESSNER, Ekkehard ,  DENGL, Stefan ,  GAERTNER, Achim

IPC分类号： A61K47/48 ,  C07K16/44 ,  C07K16/46

CPC分类号： C07K16/44 ,  A61K47/6811 ,  A61K47/6829 ,  A61K47/6879 ,  A61K2039/505 ,  C07K7/08 ,  C07K16/26 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/94 ,  C07K2319/31 ,  C07K2319/70 ,  C07K2319/73 ,  C07K2319/75

摘要： Herein is reported a conjugate comprising a helicar motif amino acid sequence containing compound and an antibody that specifically binds to the helicar motif amino acid sequence characterized by a covalent bond between the helicar motif amino acid sequence containing compound and an amino acid residue in the CDR2 of the anti-helicar antibody, whereby the CDR2 is determined according to Kabat.

摘要翻译： 本文报道了包含含有螺旋基序氨基酸序列的化合物和特异性结合螺旋基序氨基酸序列的抗体的缀合物，其特征在于含螺旋体氨基酸序列的化合物与CDR2中的氨基酸残基之间的共价键 抗螺旋抗体，由此根据Kabat测定CDR2。

公开(公告)号：EP3013861A1

公开(公告)日：2016-05-04

申请号：EP14742047.5

申请日：2014-06-24

申请人： Genentech, Inc.

发明人： EBENS, Allen J. Jr. ,  HAZEN, Meredith C. ,  HONGO, Jo-Anne ,  JOHNSTON, Jennifer W. ,  JUNTTILA, Teemu T. ,  LI, Ji ,  POLSON, Andrew G.

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K47/48

CPC分类号： C07K16/283 ,  A61K39/395 ,  A61K39/3955 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6879 ,  A61K47/6889 ,  A61K51/1045 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56

摘要： The invention provides anti~FcRH5 antibodies and immunoconjugates and methods of using the same,

摘要翻译： 本发明提供抗FcRH5抗体和免疫缀合物及其使用方法。

公开(公告)号：EP1718338B1

公开(公告)日：2015-05-06

申请号：EP05702361.6

申请日：2005-01-27

申请人： EnGeneIC Molecular Delivery Pty Ltd.

发明人： BRAHMBHATT, Himanshu ,  MACDIARMID, Jennifer

IPC分类号： A61K47/00 ,  A61K9/127

CPC分类号： A61K9/5068 ,  A61K31/704 ,  A61K47/6879 ,  A61K47/6901 ,  Y02A50/481

摘要： A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.